Sanofi Consumer Healthcare India Ltd (SANOFICONR) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sanofi Consumer Healthcare India Ltd on NSE and BSE, with an AI summary of each filing.
Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated October 28, 2026.
Outcome · 29 Oct 2026, 12:24 am
Sanofi Consumer Healthcare India Reports Q3'26 Financial Results Sanofi Consumer Healthcare India reported revenue from operations of ₹2,631 million for the quarter ended 30th Sep'26, up 12% YoY, driven by a 19% YoY rise in domestic sales. Profit before tax rose 22% YoY to ₹1,027 million, while net profit reached ₹766 million versus ₹629 million in Q3'25. Basic and diluted EPS grew 21.8% YoY to ₹33.26. For the nine-month period, revenue rose 16% YoY to ₹7,280 million, and net profit grew 22.8% YoY to ₹2,132 million.
The Board of Directors at its meeting held on Wednesday, 28th October 2026, considered and approved the Unaudited Financial Results for the quarter and nine months ended 30th September ....
Press Release · 29 Oct 2026, 12:22 am
Sanofi Consumer Healthcare India Reports Strong Q3'26 Financial Performance Sanofi Consumer Healthcare India reported Q3'26 revenue from operations of ₹2,631 million, up 12% YoY (11.6% QoQ), with product sales rising 14.4% YoY to ₹2,438 million led by 19% domestic sales growth. Profit before tax rose 22.1% YoY to ₹1,027 million, while net profit grew 21.8% YoY to ₹766 million (₹688 million in Q2'26), yielding an EPS of ₹33.26. For 9M'26, revenue increased 16.0% YoY to ₹7,280 million, PBT rose 24.2% YoY to ₹2,853 million, and net profit expanded 22.8% YoY to ₹2,132 million.
Sanofi Consumer Healthcare India Limited has submitted to the Exchange, the Unaudited Financial Results for the quarter and nine months ended September 30, 2026.
Outcome · 29 Oct 2026, 12:16 am
Sanofi Consumer Healthcare India Reports Q3'26 Financial Results Sanofi Consumer Healthcare India reported a 12.48% YoY increase in revenue from operations to ₹2,631 million for the quarter ended 30th Sep'26, compared to ₹2,339 million in the previous year quarter. Net profit rose 21.78% YoY to ₹766 million from ₹629 million, with Profit Before Tax expanding 22.12% YoY to ₹1,027 million. Basic and diluted EPS improved to ₹33.26 from ₹27.31 YoY. For 9M'26, revenue stood at ₹7,280 million, up 16.03% YoY, while net profit grew 22.81% YoY to ₹2,132 million.
Unaudited Financial Results for the quarter and nine months ended September 30, 2026 is enclosed.
Financial Result · 29 Oct 2026, 12:10 am
Sanofi Consumer Healthcare India Reports Strong Q3'26 Profit and Revenue Growth Sanofi Consumer Healthcare India reported a 12.48% YoY increase in revenue from operations to ₹2,631 million for the quarter ended 30th Sep'26, driven by a 19% YoY growth in domestic sales. Net profit rose 21.78% YoY to ₹766 million, up from ₹629 million in Q3'25, with EPS increasing 21.79% YoY to ₹33.26. Profit before tax reached ₹1,027 million, marking a 22.12% YoY increase. For the nine-month period ended 30th Sep'26, revenue increased 16.03% YoY to ₹7,280 million, while net profit grew 22.81% YoY to ₹2,132 million.
We wish to inform you that the Board of Directors at its meeting held today, i.e. Wednesday, 28th October 2026, inter alia considered and approved the Unaudited Financial Results for the ....
Outcome · 28 Oct 2026, 11:51 pm
Sanofi Consumer Healthcare India Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Million) ■ Revenue: 2,631 (+12.5% YoY | +11.6% QoQ) ■ EBITDA: 1,017 (+19.6% YoY | +13.9% QoQ) ■ EBITDA Margin (%): 38.7 (+231 bps YoY | +77 bps QoQ) ■ PAT: 766 (+21.8% YoY | +11.3% QoQ) ■ EPS (INR): 33.3 (+21.8% YoY | +11.3% QoQ)
Sanofi Consumer Healthcare India Limited has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 28 Oct 2026, 5:30 am
Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve the Unaudited ....
Intimation · 28 Oct 2026, 5:30 am
Sanofi Consumer Healthcare India Schedules Board Meeting to Approve Q3 Results Sanofi Consumer Healthcare India Limited announced that its Board of Directors will meet on 28th Oct'26 to consider and approve the unaudited financial results for the quarter and nine months ended 30th Sep'26. Additionally, the trading window for designated persons, which closed on 1st Oct'26, will remain shut until 30th Oct'26 (both days inclusive) in accordance with insider trading regulations.
Sanofi Consumer Healthcare India Limited has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 28 Oct 2026, 5:30 am
To consider and approve the Unaudited Financial Results for the quarter and nine months ended September 30, 2026
Intimation · 28 Oct 2026, 5:30 am
The Board of Directors at its meeting held on Tuesday, 28th July 2026, considered and approved the Unaudited Financial Results for the quarter and half year ended 30th June 2026. In this ....
Press Release · 29 Jul 2026, 1:34 am
Sanofi Consumer Healthcare Reports Strong Q2'26 Profit Growth Sanofi Consumer Healthcare India reported strong Q2'26 results with Revenue from Operations at ₹2,357 million, up 7% YoY, and Net Profit at ₹688 million, a 13% YoY increase. The growth was driven by a 12% rise in domestic sales, aided by product relaunches, while exports declined 9%. Profit Before Tax (PBT) grew 16% YoY to ₹919 million. For H1'26, revenue increased 18% YoY to ₹4,649 million, with PBT up 25% YoY to ₹1,826 million. EPS for the quarter was ₹29.87.
Unaudited Financial Results for the quarter and half year ended June 30, 2026 is enclosed.
Financial Result · 29 Jul 2026, 1:22 am
Sanofi Consumer Healthcare India Reports Strong Q2'26 Profit Growth Sanofi Consumer Healthcare India posted strong Q2’26 results, with net profit rising 13.3% YoY to ₹688 million. Revenue from operations grew 6.7% YoY to ₹2,357 million, driven by a 12% rise in domestic sales, aided by product relaunches. Profit before tax (PBT) increased 16% YoY to ₹919 million. For H1'26, revenue grew 18% YoY to ₹4,649 million, while net profit rose 23.4% to ₹1,366 million. Basic EPS for the quarter stood at ₹29.87, up from ₹26.36 in Q2'25.
We wish to inform you that the Board of Directors at its meeting held today, i.e. Tuesday, 28th July 2026, inter alia considered and approved the Unaudited Financial Results for the quarter ....
Outcome · 29 Jul 2026, 1:11 am
Sanofi Consumer Healthcare India Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Million) ■ Revenue: 2,357 (+6.7% YoY | +2.8% QoQ) ■ EBITDA: 893 (+27.2% YoY | +0.6% QoQ) ■ EBITDA Margin (%): 37.9 (+611 bps YoY | -86 bps QoQ) ■ PAT: 688 (+13.3% YoY | +1.5% QoQ) ■ EPS (INR): 29.9 (+13.3% YoY | +1.5% QoQ)
Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve the Unaudited ....
Intimation · 28 Jul 2026, 5:30 am
Sanofi Board Meeting on 28th Jul'26 to Approve Q2 & H1 Financial Results Sanofi Consumer Healthcare India Ltd. (BSE: 544250) has scheduled a Board of Directors meeting on 28th Jul'26. The primary agenda is to consider and approve the company's Unaudited Financial Results for the quarter and half year ending 30th Jun'26. In connection with this, the trading window for designated persons is closed from 1st Jul'26 to 30th Jul'26, inclusive. This meeting is a key event for investors awaiting the company's first-half performance data.
Appointment of Statutory Auditor of the Company.
Change in Auditor · 30 Jun 2026, 3:08 am
Sanofi Appoints PwC as Statutory Auditor for a Five-Year Term Sanofi Consumer Healthcare India shareholders approved the appointment of Price Waterhouse & Co Chartered Accountants LLP (PwC) as the new Statutory Auditor on 26th Jun'26. PwC fills the casual vacancy from the resignation of Kalyaniwalla & Mistry LLP. Following the 3rd AGM, PwC is appointed for a five-year term, effective until the conclusion of the 8th AGM in 2031. This change in auditors is a key corporate governance update for the company.
Please find eclosed Voting Results and Consolidated Scrutinizer''s Report of the 3rd Annual General Meeting held on 26th June 2026
Annual General Meeting · 30 Jun 2026, 12:47 am
Please find enclosed summary of proceeding of the 3rd Annual General Meeting of the Company held today.
Annual General Meeting · 27 Jun 2026, 12:47 am
Business Responsibility and Sustainability Report for FY 2025 is enclosed.
Others (Uncategorized) · 05 Jun 2026, 4:45 am
Sanofi Consumer Healthcare India Submits FY25 Business Responsibility and Sustainability Report Sanofi Consumer Healthcare India (SANOFICONR) has submitted its Business Responsibility and Sustainability Report for the financial year ended 31st Dec'25. Key CY25 metrics include an employee base of 518, with women comprising 18% of employees and 33% of the board. The company holds a 60.40% stake in Opella Healthcare Participations B.V. Financially, sales to the top 10 dealers represented 30.75% of total dealer sales. Related party transactions constituted 12.0% of total purchases and 25.4% of total sales. The company has no differently-abled employees.
Notice of 3rd AGM of the Company is enclosed
Annual General Meeting · 05 Jun 2026, 4:40 am
Sanofi India Proposes PwC as New Auditor and Announces Final Dividend Sanofi Consumer Healthcare will hold its 3rd AGM on 26th Jun'26 via video conference. Key proposals include declaring a final dividend of ₹75 per equity share for the year ended 31st Dec'25. Following the resignation of Kalyaniwalla & Mistry LLP, the board recommends appointing Price Waterhouse & Co Chartered Accountants LLP as statutory auditors. This appointment will first fill the casual vacancy until the AGM's conclusion and then for a five-year term until the 8th AGM in 2031, subject to shareholder approval.
Please find enclosed Annual Report for Financial Year 2025.
Others (Uncategorized) · 05 Jun 2026, 4:38 am
Sanofi Consumer Healthcare India: Notice of 3rd AGM and Annual Report FY25 Sanofi Consumer Healthcare India has released its FY25 Annual Report and announced its 3rd AGM will be held on 26th Jun'26. The company reported strong FY25 results, with Revenue from Operations up 21% YoY to ₹8,784 million and Profit After Tax growing 33% YoY to ₹2,401 million. Key agenda items for the AGM include the declaration of a final dividend of ₹75 per share, with a record date of 19th Jun'26 and payment on 9th Jul'26. The book closure period is from 20th Jun'26 to 26th Jun'26.
The record date for payment of final dividend for FY 2025 is Friday, 19th June 2026
Dividend · 27 May 2026, 11:45 pm
Sanofi Consumer Healthcare India Announces AGM and Dividend Record Date Sanofi Consumer Healthcare India (SANOFICONR) will hold its 3rd Annual General Meeting on 26th Jun'26 at 3:00 PM IST via video conference. The company has announced a record date of 19th Jun'26 for the payment of its final dividend for the financial year 2025. The register of members and share transfer books will be closed from 20th Jun'26 to 26th Jun'26 (inclusive) for this purpose. Eligible shareholders will be those on the company's register as of the record date.
This is to inform you that the 3rd Annual General Meeting of the Company will be held on Friday, 26th June 2026 through VC/OAVM facility.
Annual General Meeting · 27 May 2026, 11:34 pm
Sanofi Consumer Healthcare Sets Record Date for Final Dividend Sanofi Consumer Healthcare India will hold its 3rd AGM on 26th Jun'26 at 3:00 PM via video conference. The company has fixed 19th Jun'26 as the record date for determining shareholder eligibility for the final dividend payment. For this purpose, the Register of Members and Share Transfer Books will be closed from 20th Jun'26 to 26th Jun'26 (inclusive). The dividend amount was not specified in the notice.
Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as the Statutory Auditors of the Company to fill the casual vacancy and hold officer for a period of 5 (five) consecutive ....
Change in Auditor · 25 May 2026, 11:30 pm
Sanofi Appoints PwC as Statutory Auditor Following Resignation of Kalyaniwalla & Mistry On 25th May'26, Sanofi's Board appointed Price Waterhouse & Co Chartered Accountants LLP (PwC) as the new statutory auditor. This follows the resignation of Kalyaniwalla & Mistry LLP. PwC will first fill the casual vacancy until the upcoming AGM. Subject to shareholder approval, PwC will then serve a five-year term from the 2026 AGM until the conclusion of the AGM in 2031. This change in auditors ensures continuity in the company's financial oversight and compliance framework.
Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as the Statutory Auditors of the Company to fill the casual vacancy and hold office for a period of 5 (five) consecutive ....
Others (Uncategorized) · 25 May 2026, 11:24 pm
Sanofi Appoints PwC as New Statutory Auditor for a Five-Year Term On 25 May'26, Sanofi Consumer Healthcare's board appointed Price Waterhouse & Co Chartered Accountants LLP (PwC) as the new statutory auditor. The appointment fills the casual vacancy created by the resignation of M/s. Kalyaniwalla & Mistry LLP. Subject to shareholder approval at the upcoming AGM, PwC will hold the office for a five-year term, concluding at the AGM in 2031. This move ensures continuity in the company's audit and governance framework following the recent change.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nippon India Mutual Fund
Acquisition/ Disposal of Shares · 05 May 2026, 4:50 pm
Nippon MF raises stake in Sanofi Consumer Healthcare to over 5% Nippon India Mutual Fund, through open market transactions, acquired 30,000 shares (0.1303%) of Sanofi Consumer Healthcare India. This purchase increases its total holding from 11,32,073 shares (4.9155%) to 11,62,073 shares, crossing the 5% threshold to a new stake of 5.0458%. The transactions occurred between Jun 14, 2024, and Apr 29, 2026. The disclosure was made on May 04, '26, under SEBI's SAST regulations. Sanofi's total equity share capital remains at Rs 23,03,06,220.
This is to inform you that M/s. Kalyaniwalla & Mistry LLP, Chartered Accountants have tendered their resignation as Statutory Auditor of the Company with immediate effect.
Change in Auditor · 30 Apr 2026, 11:22 pm
Sanofi Consumer Healthcare India Statutory Auditors Resign Over Fee Disagreement Statutory auditors Kalyaniwalla & Mistry LLP resigned from Sanofi Consumer Healthcare India (SANOFICONR) effective 30 Apr'26. The resignation followed the company's inability to accommodate the auditor's request for a fee increase for FY26, which the auditor deemed necessary for commercial viability. Appointed on 25 Apr'24 for a term until FY29, the firm confirmed no other disagreements or issues prompted the resignation. The last report submitted was the limited review for the quarter ended 31 Mar'26.